Claims for Patent: 9,968,593

Summary for Patent: 9,968,593

Title:	Combination therapy for treatment of resistant bacterial infections
Abstract:	The present invention is directed to combinations of a β-lactamase inhibitor with sulbactam and, optionally, imipenem/cilastatin. The combinations are useful for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant pathogens. More particularly, the invention relates to a combination of β-lactamase inhibitor compound 1: or a pharmaceutically acceptable salt thereof, with sulbactam, or a pharmaceutically acceptable salt thereof, and, optionally, imipenem/cilastatin, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Boudewijn Lodewijk Maria DeJonge, Thomas Francois Durand-Reville, Jeroen Cunera Verheijen, Ruben Tommasi, John Mueller
Assignee:	Entasis Therapeutics Ltd
Application Number:	US15/527,091
Patent Claims:	1. A combination comprising the β-lactamase inhibitor: or a pharmaceutically acceptable salt thereof, sulbactam, or a pharmaceutically acceptable salt thereof, imipenem, or a pharmaceutically acceptable salt thereof, and cilastatin or a pharmaceutically acceptable salt thereof. 2. The combination of claim 1, wherein the β-lactamase inhibitor is in the form of a sodium salt. 3. The combination of claim 1, further comprising ampicillin or cefoperazone. 4. A method of treating bacterial infection in a subject in need thereof, comprising administering to the subject in need thereof an effective amount of the β-lactamase inhibitor: or a pharmaceutically acceptable salt thereof, an effective amount of sulbactam, or a pharmaceutically acceptable salt thereof, an effective amount of imipenem, or a pharmaceutically acceptable salt thereof, and an effective amount of cilastatin, or a pharmaceutically acceptable salt thereof. 5. The method of claim 4, wherein the β-lactamase inhibitor is in the form of a sodium salt. 6. The method of claim 4, further comprising administering ampicillin or cefoperazone. 7. The method of claim 4, wherein the bacterial infection is caused by Enterobacteriaceae. 8. The method of claim 4, wherein the bacterial infection is caused by an Acinetobacter spp. pathogen, Pseudomonas aeruginosa, or a Burkholderia spp. pathogen.